摘要:
Methods of forming a semiconductor device are provided. The methods may include forming a second insulation pattern on a first insulation pattern. The first insulation pattern may cover a plurality of conductive structures, and may include a hole therein. The second insulation pattern may include a trench therein that is connected with the hole. The methods may also include forming a spacer on sidewalls of the hole and the trench. The methods may further include forming a wiring structure in the hole and the trench.
摘要:
Disclosed are a shift register capable of reducing power consumption, a data driver having the same, and a liquid crystal display device. The shift register includes a storing cell array including storage cells which store a plurality of serial data, and a control array for outputting sampling signals, which are sequentially shifted every period of data transmission such that the storage cells sequentially store the data, in response to at least one clock signal having a frequency lower than a transmission frequency of the data.
摘要:
The present invention relates to a method of preparing an ethylene-α-olefin-diene copolymer and an ethylene-α-olefin-diene copolymer prepared thereby, by using a transition metal compound based on a cyclopenta[b]fluorenyl group as a catalyst.
摘要:
This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same.The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.
摘要:
The present invention relates to a new transition metal compound based on cyclopenta[b]fluorenyl group, a transition metal catalyst composition containing the same and having high catalytic activity for preparing an ethylene homopolymer or a copolymer of ethylene and one α-olefin, a method of preparing an ethylene homopolymer or a copolymer of ethylene and α-olefin using the same, and the prepared ethylene homopolymer or the copolymer of ethylene and α-olefin.
摘要:
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same.The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.
摘要:
An electric socket is provided. The socket includes a power saving circuit determining operation status of an electronic apparatus or plural electronic apparatus connected to another electric socket according to a load signal to control to supply or automatically interrupt power. It is possible to control power according to operating status of the connected electronic apparatus and to control power supplied to the electronic apparatus connected to a home network. After time has elapsed when the electronic apparatus is not used, power is automatically interrupted so that undesired power consumption due to standby power can be prevented and costs thereof are significantly saved. The electronic apparatus is prevented from accident load inputted from the exterior so that the lifespan of the electronic apparatus can be elongated and user convenience is remarkably improved.
摘要:
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.